vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Dolby Laboratories, Inc. (DLB). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $205.4M, roughly 1.9× COLLEGIUM PHARMACEUTICAL, INC). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs 8.3%, a 15.7% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 7.1%). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 13.9%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
COLL vs DLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $395.6M |
| Net Profit | $17.0M | $94.9M |
| Gross Margin | 62.5% | 88.7% |
| Operating Margin | 29.6% | 28.5% |
| Net Margin | 8.3% | 24.0% |
| Revenue YoY | 12.9% | 7.1% |
| Net Profit YoY | 35.3% | 3.4% |
| EPS (diluted) | $0.48 | $0.99 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $395.6M | ||
| Q1 26 | — | $346.7M | ||
| Q4 25 | $205.4M | $346.7M | ||
| Q3 25 | $209.4M | $307.0M | ||
| Q2 25 | $188.0M | $315.5M | ||
| Q1 25 | $177.8M | $369.6M | ||
| Q4 24 | $181.9M | $357.0M | ||
| Q3 24 | $159.3M | $304.8M |
| Q2 26 | — | $94.9M | ||
| Q1 26 | — | $53.3M | ||
| Q4 25 | $17.0M | $53.3M | ||
| Q3 25 | $31.5M | $49.3M | ||
| Q2 25 | $12.0M | $46.1M | ||
| Q1 25 | $2.4M | $91.8M | ||
| Q4 24 | $12.5M | $67.8M | ||
| Q3 24 | $9.3M | $58.6M |
| Q2 26 | — | 88.7% | ||
| Q1 26 | — | 87.5% | ||
| Q4 25 | 62.5% | 87.5% | ||
| Q3 25 | 61.7% | 87.1% | ||
| Q2 25 | 57.7% | 86.1% | ||
| Q1 25 | 54.8% | 90.3% | ||
| Q4 24 | 54.0% | 88.6% | ||
| Q3 24 | 60.8% | 88.8% |
| Q2 26 | — | 28.5% | ||
| Q1 26 | — | 17.9% | ||
| Q4 25 | 29.6% | 17.9% | ||
| Q3 25 | 29.7% | 9.7% | ||
| Q2 25 | 18.7% | 15.1% | ||
| Q1 25 | 12.2% | 29.2% | ||
| Q4 24 | 20.9% | 22.4% | ||
| Q3 24 | 21.9% | 15.2% |
| Q2 26 | — | 24.0% | ||
| Q1 26 | — | 15.4% | ||
| Q4 25 | 8.3% | 15.4% | ||
| Q3 25 | 15.0% | 16.1% | ||
| Q2 25 | 6.4% | 14.6% | ||
| Q1 25 | 1.4% | 24.8% | ||
| Q4 24 | 6.9% | 19.0% | ||
| Q3 24 | 5.9% | 19.2% |
| Q2 26 | — | $0.99 | ||
| Q1 26 | — | $0.55 | ||
| Q4 25 | $0.48 | $0.55 | ||
| Q3 25 | $0.84 | $0.50 | ||
| Q2 25 | $0.34 | $0.48 | ||
| Q1 25 | $0.07 | $0.94 | ||
| Q4 24 | $0.36 | $0.70 | ||
| Q3 24 | $0.27 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $594.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $2.6B |
| Total Assets | $1.7B | $3.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $594.7M | ||
| Q1 26 | — | $644.6M | ||
| Q4 25 | $386.7M | $644.6M | ||
| Q3 25 | $285.9M | $702.6M | ||
| Q2 25 | $222.2M | $699.3M | ||
| Q1 25 | $197.8M | $626.6M | ||
| Q4 24 | $162.8M | $520.8M | ||
| Q3 24 | $120.0M | $482.0M |
| Q2 26 | — | $2.6B | ||
| Q1 26 | — | $2.6B | ||
| Q4 25 | $301.7M | $2.6B | ||
| Q3 25 | $274.8M | $2.6B | ||
| Q2 25 | $232.2M | $2.6B | ||
| Q1 25 | $234.4M | $2.6B | ||
| Q4 24 | $228.8M | $2.5B | ||
| Q3 24 | $234.3M | $2.5B |
| Q2 26 | — | $3.2B | ||
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.7B | $3.2B | ||
| Q3 25 | $1.6B | $3.2B | ||
| Q2 25 | $1.6B | $3.2B | ||
| Q1 25 | $1.6B | $3.2B | ||
| Q4 24 | $1.7B | $3.2B | ||
| Q3 24 | $1.6B | $3.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $147.3M |
| Free Cash FlowOCF − Capex | $122.4M | — |
| FCF MarginFCF / Revenue | 59.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 7.25× | 1.55× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $147.3M | ||
| Q1 26 | — | $54.8M | ||
| Q4 25 | $123.0M | $54.8M | ||
| Q3 25 | $78.4M | $472.2M | ||
| Q2 25 | $72.4M | $67.7M | ||
| Q1 25 | $55.4M | $174.9M | ||
| Q4 24 | $84.6M | $106.8M | ||
| Q3 24 | $-9.0M | $327.3M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $122.4M | $50.2M | ||
| Q3 25 | $78.3M | $435.9M | ||
| Q2 25 | $72.4M | $61.3M | ||
| Q1 25 | $54.6M | $168.0M | ||
| Q4 24 | $84.1M | $100.0M | ||
| Q3 24 | $-9.2M | $297.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 59.6% | 14.5% | ||
| Q3 25 | 37.4% | 142.0% | ||
| Q2 25 | 38.5% | 19.4% | ||
| Q1 25 | 30.7% | 45.5% | ||
| Q4 24 | 46.2% | 28.0% | ||
| Q3 24 | -5.8% | 97.5% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 1.3% | ||
| Q3 25 | 0.1% | 11.8% | ||
| Q2 25 | 0.0% | 2.0% | ||
| Q1 25 | 0.4% | 1.9% | ||
| Q4 24 | 0.3% | 1.9% | ||
| Q3 24 | 0.2% | 9.8% |
| Q2 26 | — | 1.55× | ||
| Q1 26 | — | 1.03× | ||
| Q4 25 | 7.25× | 1.03× | ||
| Q3 25 | 2.49× | 9.57× | ||
| Q2 25 | 6.05× | 1.47× | ||
| Q1 25 | 22.92× | 1.91× | ||
| Q4 24 | 6.75× | 1.57× | ||
| Q3 24 | -0.96× | 5.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
